Loading...
Market
Teva generic liraglutide market share in diabetes treatment by end of 2024
4
Resolution / Starting Odds
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Market share reports from pharmaceutical market analytics firms
Story
Teva Launches First Generic GLP-1 Drug, Liraglutide (Victoza)
Jun 26, 2024, 10:01 AM
On June 24, 2024, Teva launched the first generic version of Novo Nordisk's GLP-1 receptor agonist drug, liraglutide, known commercially as Victoza. This generic introduction marks a significant milestone in the diabetes and obesity medication market. The higher dose of 3mg daily, which is used for obesity, could potentially make the treatment more accessible to those in need. However, experts are cautious about immediate price reductions, citing market inertia and other factors.
View original story
Similar markets
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Less than 20% • 33%
20% - 50% • 33%
More than 50% • 34%
Increase by less than 5% • 33%
Increase by 5% to 10% • 34%
Increase by more than 10% • 33%
Wegovy • 25%
Zepbound • 25%
Ozempic • 25%
Other • 25%
Less than 20% • 33%
20% to 40% • 33%
More than 40% • 34%
Below 20% • 25%
20% to 30% • 25%
30% to 40% • 25%
Above 40% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Zepbound • 25%
Wegovy • 25%
Ozempic • 25%
Other • 25%
Novo Nordisk • 25%
Eli Lilly • 25%
Pfizer • 25%
Other • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 25% • 25%
25-35% • 25%
35-45% • 25%
More than 45% • 25%
0-10% • 25%
11-25% • 25%
26-50% • 25%
More than 50% • 25%